keyword
MENU ▼
Read by QxMD icon Read
search

Mixed Amphetamine Salts

keyword
https://www.readbyqxmd.com/read/29775957/how-treatment-improvement-in-adhd-and-cocaine-dependence-are-related-to-one-another-a-secondary-analysis
#1
Frances R Levin, C Jean Choi, Martina Pavlicova, John J Mariani, Amy Mahony, Daniel J Brooks, Edward V Nunes, John Grabowski
BACKGROUND: Attention-deficit hyperactivity disorder (ADHD) is overrepresented among individuals seeking treatment for substance use disorders. We previously reported that treatment with extended release mixed amphetamine salts (MAS-XR) increased abstinence, compared to placebo, among patients with co-occurring ADHD and cocaine dependence. This secondary analysis investigates the temporal relationship between ADHD improvement and cocaine abstinence in the first six weeks of the trial...
May 1, 2018: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/29460165/efficacy-and-safety-of-drugs-for-attention-deficit-hyperactivity-disorder-in-children-and-adolescents-a-network-meta-analysis
#2
Sarah C O S Padilha, Suzane Virtuoso, Fernanda S Tonin, Helena H L Borba, Roberto Pontarolo
The aim of this study is to gather evidence of head-to-head double-blind randomized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder (ADHD) in children and adolescents. A systematic review was conducted by two independent reviewers in ten electronic databases (PROSPERO register CRD42016043239). Methodological quality of included studies was evaluated according to the Jadad scale. Network meta-analyses were performed including double-blinded head-to-head trials comparing active allopathic drugs in patients (0-18 years old) diagnosed with ADHD...
February 19, 2018: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/29346342/attention-deficit-hyperactivity-disorder-medication-prescription-claims-among-privately-insured-women-aged-15-44-years-united-states-2003-2015
#3
Kayla N Anderson, Elizabeth C Ailes, Melissa Danielson, Jennifer N Lind, Sherry L Farr, Cheryl S Broussard, Sarah C Tinker
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects individuals across the lifespan. ADHD medication use among pregnant women is increasing (1), but consensus about the safety of ADHD medication use during pregnancy is lacking. Given that nearly half of U.S. pregnancies are unintended (2), and early pregnancy is a critical period for fetal development, examining trends in ADHD medication prescriptions among reproductive-aged women is important to quantify the population at risk for potential exposure...
January 19, 2018: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/29316800/pro-dopamine-regulator-kb220z-attenuates-hoarding-and-shopping-behavior-in-a-female-diagnosed-with-sud-and-adhd
#4
Thomas McLaughlin, Kenneth Blum, Bruce Steinberg, Edward J Modestino, Lyle Fried, David Baron, David Siwicki, Eric R Braverman, Rajendra D Badgaiyan
Background Addictive-like behaviors (e.g., hoarding and shopping) may be the result of the cumulative effects of dopaminergic and other neurotransmitter genetic variants as well as elevated stress levels. We, therefore, propose that dopamine homeostasis may be the preferred goal in combating such challenging and unwanted behaviors, when simple dopaminergic activation through potent agonists may not provide any resolution. Case presentation C.J. is a 38-year-old, single, female, living with her mother. She has a history of substance use disorder as well as attention deficit hyperactivity disorder, inattentive type...
March 1, 2018: Journal of Behavioral Addictions
https://www.readbyqxmd.com/read/29192549/a-single-dose-two-way-crossover-open-label-bioequivalence-study-of-an-amphetamine-extended-release-oral-suspension-in-healthy-adults
#5
Carolyn Sikes, Jeffrey G Stark, Russ McMahen, Dorothy Engelking
OBJECTIVE: The purpose of this study was to compare the pharmacokinetics of a new extended-release amphetamine oral suspension (AMP XR-OS) with a standard extended-release mixed amphetamine salts product, Adderall XR®. METHOD: In this single-dose, open-label, randomized, two-period, two-treatment crossover study, 42 healthy adult volunteers received 15 mL of AMP XR-OS in one period and a 30 mg Adderall XR capsule in another period (both containing 18.8 mg of amphetamine base) under fasted conditions...
November 1, 2017: Journal of Attention Disorders
https://www.readbyqxmd.com/read/29186993/medication-use-in-adults-with-attention-deficit-hyperactivity-disorder-in-a-commercially-insured-population-in-the-united-states
#6
Zhou Zhou, Zheng-Yi Zhou, Sneha S Kelkar, Vanja Sikirica, Jipan Xie, Regina Grebla
OBJECTIVE: To examine real-world prescription medication usage among commercially-insured adults with attention deficit/hyperactivity disorder (ADHD) in the US. METHODS: Adults with ADHD who received ≥1 ADHD medication during 2013 were identified from a large US claims database. Combination therapy was defined as an overlap of ≥30 days between the index (first treatment ≥30 days in 2013) and another medication(s). Patients were classified into six groups: long-acting (LA) monotherapy, short-acting (SA) monotherapy, LA + LA, SA + SA, LA + SA, and >2 therapies...
April 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29174216/pharmacokinetics-of-a-new-amphetamine-extended-release-oral-liquid-suspension-under-fasted-and-fed-conditions-in-healthy-adults-a-randomized-open-label-single-dose-3-treatment-study
#7
Carolyn Sikes, Jeffrey G Stark, Russ McMahen, Dorothy Engelking
PURPOSE: A new amphetamine extended-release liquid formulation (AMP XR-OS), intended for the treatment of attention-deficit/hyperactivity disorder, has been developed. This study was performed to determine if administration with food affected the rate of absorption or bioavailability of AMP XR-OS. The formulation was also compared with an equivalent dose of an extended-release mixed amphetamine salts reference product (30 mg) under fed conditions. METHODS: Thirty adult volunteers participated in this single-dose, open-label, randomized, 3-period, 3-treatment crossover study...
December 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29052031/do-pharmaceuticals-improve-driving-in-individuals-with-adhd-a-review-of-the-literature-and-evidence-for-clinical-practice
#8
REVIEW
Craig B H Surman, Ronna Fried, Lauren Rhodewalt, Heidi Boland
Attention-deficit/hyperactivity disorder (ADHD) is defined as a disorder of impaired attention and/or behavioral control. Studies suggest that the condition can dispose individuals to a higher risk of automobile accidents. ADHD symptoms respond to pharmacotherapy in a majority of uncomplicated cases. Evidence on how pharmacotherapies for ADHD impact driving behavior or outcomes could allow clinicians to support on-road safety rationally. We therefore undertook a review to identify the evidence base to date indicating positive or negative effects of pharmacotherapies on driving behavior in individuals with ADHD...
October 2017: CNS Drugs
https://www.readbyqxmd.com/read/28933918/pharmacokinetics-of-a-new-amphetamine-extended-release-oral-suspension-in-children-with-attention-deficit-hyperactivity-disorder
#9
Carolyn R Sikes, Russ L McMahen, Jeffrey G Stark, Dorothy Engelking
OBJECTIVE: An extended-release amphetamine (AMP) oral suspension has been developed to facilitate medication ingestion and dose titration. This study sought to determine the pharmacokinetic (PK) profile of this new formulation in children with attention-deficit/hyperactivity disorder (ADHD). METHODS: This was an open-label, single-period, PK study in 29 pediatric participants with ADHD. Participants were stratified into age groups 1 (6-7 years), 2 (8-9 years), and 3 (10-12 years), and dosed with 15 mL extended-release AMP liquid suspension (equivalent to 30 mg mixed AMP salts) after an overnight fast...
February 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28910145/the-clinical-pharmacokinetics-of-amphetamines-utilized-in-the-treatment-of-attention-deficit-hyperactivity-disorder
#10
REVIEW
John S Markowitz, Kennerly S Patrick
Amphetamine (AMP), an indirectly acting psychostimulant approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults, is among the most long-standing therapeutic agents in all of clinical psychopharmacology. This review focuses on AMP absorption, metabolism, and elimination brought to bear on comparative pharmacokinetics in its various formulations. A comprehensive search of the published literature was conducted using MEDLINE (PubMed) and Google Scholar databases through April 2017 to retrieve all pertinent in vitro and human studies for review and synthesis...
October 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28816509/shp465-mixed-amphetamine-salts-in-the-treatment-of-attention-deficit-hyperactivity-disorder-in-children-and-adolescents-results-of-a-randomized-double-blind-placebo-controlled-study
#11
Matthew Brams, Ann C Childress, Michael Greenbaum, Ming Yu, Brian Yan, Margo Jaffee, Brigitte Robertson
OBJECTIVE: The aim of this study was to evaluate the efficacy, safety, and tolerability of SHP465 mixed amphetamine salts (MAS) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). METHODS: This randomized, double-blind dose-optimization study enrolled children and adolescents (6-17 years) meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision ADHD criteria and having baseline ADHD Rating Scale IV (ADHD-RS-IV) total scores ≥28...
February 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28712074/efficacy-and-safety-of-shp465-mixed-amphetamine-salts-in-the-treatment-of-attention-deficit-hyperactivity-disorder-in-adults-results-of-a-randomized-double-blind-placebo-controlled-forced-dose-clinical-study
#12
RANDOMIZED CONTROLLED TRIAL
Richard H Weisler, Michael Greenbaum, Valerie Arnold, Ming Yu, Brian Yan, Margo Jaffee, Brigitte Robertson
OBJECTIVE: The objective of this randomized, double-blind, placebo-controlled study was to evaluate the efficacy and safety of SHP465 mixed amphetamine salts (MAS) in adults with attention-deficit/hyperactivity disorder (ADHD). METHODS: Eligible adults [aged 18-55 years; meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition ADHD criteria; baseline ADHD Rating Scale with Adult Prompts (ADHD-RS-AP) total scores ≥28] were randomized 1:1:1 to placebo or forced-dose SHP465 MAS (12...
August 2017: CNS Drugs
https://www.readbyqxmd.com/read/28686989/mixed-amphetamine-salts-expectancies-among-college-students-is-stimulant-induced-cognitive-enhancement-a-placebo-effect
#13
Karen L Cropsey, Samantha Schiavon, Peter S Hendricks, Morgan Froelich, Iga Lentowicz, Rachel Fargason
INTRODUCTION: Non-medical use of prescription stimulants for cognitive enhancement in college students is increasing, despite evidence showing little benefit in non-clinical populations. The balanced placebo design (BPD) was used to independently evaluate the pharmacologic versus expectancy effects of mixed amphetamine salts on cognitive performance among a non-clinical sample of college-aged students. METHOD: Participants were screened and excluded for ADHD and other psychopathologies...
September 1, 2017: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28413925/triple-bead-mixed-amphetamine-salts-shp465-in-adults-with-adhd-results-of-a-phase-3-double-blind-randomized-forced-dose-trial
#14
Glen Frick, Brian Yan, Lenard A Adler
OBJECTIVE: Evaluate the efficacy and tolerability of triple-bead mixed amphetamine salts (MAS) in ADHD. METHOD: Adults with ADHD Rating Scale IV (ADHD-RS-IV) total scores ≥32 were randomized to 6 weeks of triple-bead MAS (25, 50, or 75 mg) or placebo. The primary endpoint was ADHD-RS-IV total score change from baseline at end of study (EOS). RESULTS: Least squares mean (95% confidence interval [CI]) treatment differences for ADHD-RS-IV total score changes from baseline to EOS significantly favored triple-bead MAS (all doses combined: -10...
April 1, 2017: Journal of Attention Disorders
https://www.readbyqxmd.com/read/28412886/a-long-term-open-label-safety-study-of-triple-bead-mixed-amphetamine-salts-shp465-in-adults-with-adhd
#15
Lenard A Adler, Glen Frick, Brian Yan
OBJECTIVE: The aim of this study was to evaluate the long-term safety of triple-bead mixed amphetamine salts (MAS) in adults with ADHD. METHOD: Adults meeting Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.; DSM-IV-TR) ADHD criteria and satisfying study criteria from one of two antecedent studies were enrolled in this 52-week (dose titration, 4 weeks; dose maintenance, 11 months) open-label extension. The protocol included 12.5- to 75-mg triple-bead MAS but was amended to a maximum of 50-mg triple-bead MAS...
April 1, 2017: Journal of Attention Disorders
https://www.readbyqxmd.com/read/28366111/safety-of-treatments-for-adhd-in-adults-pairwise-and-network-meta-analyses
#16
Danielly Chierrito de Oliveira, Patricia Guerrero de Sousa, Camila Borges Dos Reis, Fernanda Stumpf Tonin, Laiza Maria Steimbach, Suzane Virtuoso, Fernando Fernandez-Llimos, Roberto Pontarolo, Andréia Cristina Conegero Sanches
OBJECTIVE: The aim of the study was to analyze evidence comparing the profile of drugs used to treat ADHD in adult patients. METHOD: Systematic searches were conducted in electronic databases. Randomized, double-blind, parallel controlled trials that evaluated the safety of drugs in ADHD were included. The statistical analyses were conducted by pairwise meta-analyses and mixed treatment comparison (MTC). RESULTS: Ten ( n = 3006) trials were included in the analyses...
March 1, 2017: Journal of Attention Disorders
https://www.readbyqxmd.com/read/28141724/inattentive-attention-deficit-hyperactivity-disorder-stimulant-medication-and-weight-loss-in-a-15-year-old-girl-are-we-enabling-the-development-of-an-eating-disorder
#17
Sai Iyer, Maya Kumar, Michael I Reiff, Martin T Stein
Nicole is a 15-year-old girl presenting to the Developmental Behavioral Pediatrics Clinic with symptoms of the inattentive type of Attention-Deficit/Hyperactivity Disorder (ADHD) and declining school performance over the last year. She expressed frustration over her inability to concentrate on schoolwork. Assuming that her poor grades were secondary to lack of effort, her parents withdrew privileges. Nicole became increasingly depressed. She stopped participating in activities, she previously enjoyed, and her parents reported that she stopped singing in the shower...
February 2017: Journal of Developmental and Behavioral Pediatrics: JDBP
https://www.readbyqxmd.com/read/28051838/mixed-amphetamine-salts-increase-abstinence-from-marijuana-in-patients-with-co-occurring-attention-deficit-hyperactivity-disorder-and-cocaine-dependence
#18
RANDOMIZED CONTROLLED TRIAL
Daniel P Notzon, John J Mariani, Martina Pavlicova, Andrew Glass, Amy L Mahony, Daniel J Brooks, John Grabowski, Frances R Levin
BACKGROUND AND OBJECTIVES: The prevalence of ADHD is greater in substance use disorders than the general population, and ADHD and substance use disorders share neurobiological features such as dysregulation of reward circuitry. We tested the hypothesis that stimulants would decrease marijuana use in a randomized controlled trial of extended release mixed amphetamine salts (MAS-XR) for treatment of co-occurring ADHD and cocaine use disorders. METHODS: Marijuana users were defined as participants reporting use in the 30 days before study initiation, collected with timeline follow-back...
December 2016: American Journal on Addictions
https://www.readbyqxmd.com/read/28009538/excessive-masturbation-association-with-mixed-amphetamine-salts
#19
Anita A Joseph, Anuradha Reddy
No abstract text is available yet for this article.
April 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/27993933/pharmacological-and-non-pharmacological-treatment-of-adults-with-adhd-a-meta-review
#20
Franco De Crescenzo, Samuele Cortese, Nicoletta Adamo, Luigi Janiri
Attention-deficit/hyperactivity disorder (ADHD) is characterised by a persistent and impairing pattern of inattention and/or hyperactivity/impulsivity and it is one of the most common neuropsychiatric conditions. Evidence about interventions of adults with ADHD is growing rapidly and clinicians need a reliable summary of all the best available information in order to better inform their daily practice. We searched MEDLINE, PubMed, PsycINFO and Cochrane databases until 31 May 2016 for systematic reviews about pharmacological and non-pharmacological treatments in adults with ADHD and carried out a meta-review to address clinically relevant questions...
February 2017: Evidence-based Mental Health
keyword
keyword
101131
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"